Skip to main content
. Author manuscript; available in PMC: 2013 May 13.
Published in final edited form as: AJR Am J Roentgenol. 2013 Mar;200(3):475–483. doi: 10.2214/AJR.12.9049

Fig. 1.

Fig. 1

Schematic shows current targeted cancer therapies approved by the Food and Drug Administration and their interactions with their primary molecular targets. EGFR = epidermal growth factor receptor, ErbB2 (formerly, HER2) = human epidermal growth factor, VEGF = vascular endothelial growth factor, VEGFR = VEGF receptor, KIT = stem cell factor receptor, ALK-FP = anaplastic lymphoma kinase fusion protein.